Clinical trials: Type 2 Diabetic Kidney Disease
Diabetes Type 2, Kidney Disease
Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial
This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease…
- Trial name
- StenoFOODApp (NCT07485075)
- Testing
- StenoFood App
- Where
- 2 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type 2 Diabetes, Hypertension
Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.
- Conditions
- Type 2 Diabetes, Hypertension, Dyslipidemia, Diabetic Nephropathy
- Trial name
- NCT00419484
- Testing
- pioglitazone
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Dokkyo Medical University
Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
The increase in the prevalence of diabetes mellitus (DM) is one of the greatest public health challenges worldwide. Epidemiological studies have shown that DM is the leading cause of chronic kidney disease (CKD) in patients…
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Polymorphism
- Trial name
- CURCUNRF2 (NCT03262363)
- Testing
- Curcumin/NFE2L2 A>G
- Where
- Mexico
- Volunteers
- 176 people
- Sponsor
- Unidad de Investigacion Medica en Enfermedades Renales
Type 2 Diabetes, Chronic Kidney Disease
Kidney Biopsy Indications in Type 2 Diabetes Patients
The WHO (World Health Organisation) estimated the prevalence of diabetes to be 422 million people in 2014, compared to 108 million in 1980.
- Trial name
- RIB-R2D2 (NCT04006028)
- Where
- 4 sites in France
- Volunteers
- 500 people
- Sponsor
- Rennes University Hospital
Type 2 Diabetes, Diabetic Kidney Disease
Mechanism of SGLT2 Inhibition in the Kidney
The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in…
- Trial name
- NCT06291155
- Testing
- SGLT2 inhibitor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Diabetes Mellitus, Type 2, Liver Diseases
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders
This is a prospective, multicentric, non-treatment study to build and validate a portable, non-invasive smart breath analyzer that can screen underlying health issues using exhaled breath.
- Conditions
- Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases
- Trial name
- RESPYR-SBA (NCT07646015)
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Respyr
Diabetic Nephropathy
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic patients they can not hinder the…
- Trial name
- NCT00663949
- Testing
- Captopril, Captopril + Pentoxifylline
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis
This is a single-center prospective observational clinical study conducted at the First Affiliated Hospital of Chongqing Medical University.
- Trial name
- NCT07717697
- Testing
- Finerenone
- Volunteers
- 425 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Diabetes Mellitus, Type 2, Kidney Failure, Chronic
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to…
- Conditions
- Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
- Trial name
- NCT00108485
- Testing
- Extended release niacin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Diabetic Nephropathies
Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy
Diabetes mellitus is a chronic disease that affects 366 million people worldwide ( 6.4 % of the adult population ) and is expected to rise to 522 million by 2030 .
- Trial name
- NCT03212755
- Testing
- serum immunoglobulin G level
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetic Nephropathy
Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy
Diabetic nephropathy, the leading cause of end-stage renal disease in many countries, is characterized by high cardiovascular mortality and morbidity even in the early course of the disease.
- Trial name
- NCT01796418
- Testing
- Beraprost sodium
- Where
- 5 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- Seoul National University Hospital